3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioblastoma
18
Glioma
11
Neoplasms
6
Brain Neoplasms
6
Astrocytoma
6
Neuroblastoma
4
Sarcoma, Ewing
3
Gliosarcoma
3
Sarcoma
2
Rhabdomyosarcoma
2
Recurrence
2
Pancreatic Neoplasms
2
Medulloblastoma
2
Diffuse Intrinsic Pontine Glioma
2
Wilms Tumor
1
Spinal Cord Neoplasms
1
Rhabdoid Tumor
1
Refractory Solid Tumors
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasm Metastasis
1
Melanoma, Cutaneous Malignant
1
Melanoma
1
Lymphoma, Follicular
1
Hepatoblastoma
1
Ganglioneuroblastoma
1
Interventions
Biopsy
5
X-Rays
4
Specimen Handling
4
Phantoms, Imaging
4
Nuclear Medicine Department, Hospital
4
Magnetic Resonance Spectroscopy
4
larotrectinib
2
erdafitinib
2
ensartinib
2
ulixertinib
1
tipifarnib
1
tazemetostat
1
selpercatinib
1
palbociclib
1
olaparib
1
niraparib
1
ivosidenib
1
elacestrant
1
cabozantinib
1
alectinib
1
abemaciclib
1
Vincristine
1
Vinblastine
1
Vemurafenib
1
Topotecan
1
Temozolomide
1
RAD1901
1
Methotrexate
1
LY3023414
1
Induction Chemotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Central Nervous System Neoplasms
×
Temozolomide
×
30 days
×
Clear all
NCT07243470
2026-05-27
TARLATEM
Centre Leon Berard
Phase 1/2
Recruiting
70 enrolled